Macro Biologics

Macro Biologics’ innovative technology platform creates synthetic biological polymers (macro biologics) for breakthrough therapeutics, next-generation medical devices, and advanced biomaterials safe for the environment. Our first class of synthetic macro biologics, Amicidins, combine a beneficial physical mode-of-action (barrier or surfactant) and broad microbicidal mode-of-action, including against antibiotic resistant bacteria. Their composition (amino acids), size, and self-assembly into multimers, yield a high level of performance and safety when applied to exposed tissues. Our first focus is prevention and treatment of life-threating infections in surgery & trauma – INDs are in preparation for Amicidin-α Surgical and Amicidin-β Solution; human clinical trials are expected to follow. Going forward, we anticipate Amicidins will go into a wide variety of products ranging from human therapeutics and devices to veterinary medicine / pet care to consumer health and cosmetics.